- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
Patent holdings for IPC class A61P 21/04
Total number of patents in this class: 558
10-year publication summary
|
11
|
21
|
23
|
27
|
38
|
34
|
42
|
36
|
31
|
38
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2721 |
23 |
| Daiichi Sankyo Company, Limited | 1879 |
16 |
| Nippon Shinyaku Co., Ltd. | 324 |
15 |
| Alexion Pharmaceuticals, Inc. | 639 |
14 |
| National Center of Neurology and Psychiatry | 151 |
13 |
| NMD Pharma A/S | 43 |
13 |
| The University of Tokyo | 4250 |
11 |
| Eloxx Pharmaceuticals Ltd. | 18 |
11 |
| Chugai Seiyaku Kabushiki Kaisha | 1379 |
8 |
| Osaka University | 3377 |
8 |
| Astellas Pharma Inc. | 1057 |
7 |
| Scholar Rock, Inc. | 125 |
7 |
| argenx, besloten vennootschap | 203 |
7 |
| Das-mg, Inc. | 7 |
7 |
| Alzprotect | 21 |
5 |
| KYORIN Pharmaceutical Co., Ltd. | 169 |
5 |
| Mitsubishi Tanabe Pharma Corporation | 560 |
5 |
| National University Corporation Tokyo Medical and Dental University | 520 |
5 |
| Ono Pharmaceutical Co., Ltd. | 428 |
5 |
| Ra Pharmaceuticals, Inc. | 45 |
5 |
| Other owners | 368 |